alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Disease mechanisms in lab and animal studies

1,352 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Amyloid-beta aggregation implicates multiple pathways in Alzheimer's disease: Understanding the mechanisms

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in neuroscience 2023-04-11 Drug development

    Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by tau pathology and accumulations of neurofibrillary tangles (NFTs) along with amyloid-beta (Aβ).

  2. Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. mAbs 2023-01-01 Treatments

    There are few treatments that slow neurodegeneration in Alzheimer's disease (AD), and while therapeutic antibodies are being investigated in clinical trials for AD treatment, their access to the central nervous system is restricted by the blood-brain barrier.

  3. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022-10-17 Treatments

    Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of Alzheimer's disease (AD).

  4. Genetics, Functions, and Clinical Impact of Presenilin-1 (PSEN1) Gene

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. International journal of molecular sciences 2022-09-19 Risk factors

    Presenilin-1 (PSEN1) has been verified as an important causative factor for early onset Alzheimer's disease (EOAD).

  5. CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Translational neurodegeneration 2022-09-15 Biomarkers

    These results suggest that the targeted methylation of APP via dCas9-Dnmt3a treatment can be a potential therapeutic strategy for AD.

  6. Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neural regeneration research 2022-08-01 Drug development

    Alzheimer's disease is a neurodegenerative disease that accounts for most of the 50-million dementia cases worldwide in 2018.

  7. The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Acta neuropathologica communications 2022-04-13 Down syndrome and Alzheimer's

    Amyloid plaques contain many proteins in addition to beta amyloid (Aβ).

  8. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Translational neurodegeneration 2022-03-18 Treatments

    Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly worldwide.

  9. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. International journal of molecular sciences 2022-02-06 Vascular contributions

    Neurodegenerative disorders are primarily characterized by neuron loss.

  10. Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Translational neurodegeneration 2022-01-28 Disease mechanisms

    Synaptic abnormalities are a cardinal feature of Alzheimer's disease (AD) that are known to arise as the disease progresses.

  11. Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Nature biomedical engineering 2022-01-06 Digital health tools

    A reduced removal of dysfunctional mitochondria is common to aging and age-related neurodegenerative pathologies such as Alzheimer's disease (AD).

  12. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. RNA biology 2021-12-31 Drug development

    RNA therapeutics comprise a diverse group of oligonucleotide-based drugs such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and short hairpin RNAs (shRNAs) that can be designed to selectively interact with drug targets currently undruggable with small molecule-based drugs or monoclonal antibodies.

  13. In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Science advances 2021-10-29 Brain scans and imaging

    Both the replication of protein aggregates and their spreading throughout the brain are implicated in the progression of Alzheimer’s disease (AD).

  14. Cellular and pathological heterogeneity of primary tauopathies

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Molecular neurodegeneration 2021-08-23 Genetics

    Microtubule-associated protein tau is abnormally aggregated in neuronal and glial cells in a range of neurodegenerative diseases that are collectively referred to as tauopathies.

  15. Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2021-08-02 Digital health tools

    Alzheimer's disease (AD) is a progressive neurodegenerative disease with no cure.

  16. Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in aging neuroscience 2021-07-23 Genetics

    The ability to investigate therapeutic interventions in animal models of neurodegenerative diseases depends on extensive characterization of the model(s) being used.

  17. Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Protein & cell 2021-07-21 Drug development

    Chaperone-mediated autophagy (CMA) is a lysosome-dependent selective degradation pathway implicated in the pathogenesis of cancer and neurodegenerative diseases.

  18. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. International journal of molecular sciences 2021-06-14 Treatments

    A large body of clinical and nonclinical evidence supports the role of neurotoxic soluble beta amyloid (amyloid, Aβ) oligomers as upstream pathogenic drivers of Alzheimer's disease (AD).

  19. "Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Molecular neurodegeneration 2021-06-05 Drug development

    Phosphorylation is one of the most prevalent post-translational modifications found in aggregated tau isolated from Alzheimer's disease (AD) patient brains.

  20. SORL1 deficiency in human excitatory neurons causes APP-dependent defects in the endolysosome-autophagy network

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Cell reports 2021-06-01 Drug development

    Dysfunction of the endolysosomal-autophagy network is emerging as an important pathogenic process in Alzheimer's disease.

  21. Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Translational neurodegeneration 2021-05-20 Drug development

    Precursor messenger RNA (pre-mRNA) splicing is a fundamental step in eukaryotic gene expression that systematically removes non-coding regions (introns) and ligates coding regions (exons) into a continuous message (mature mRNA).

  22. Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of nanobiotechnology 2021-04-29 Biomarkers

    Increasing life expectancy has led to an aging population, which has consequently increased the prevalence of dementia.

  23. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Brain : a journal of neurology 2021-03-01 Biomarkers

    Tau is a microtubule associated protein in the brain that aggregates in Alzheimer's disease to form pathological tangles and neurites.

  24. C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Autophagy 2021-02-26 Drug development

    Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two clinically distinct classes of neurodegenerative disorders.

  25. Mitovesicles are a novel population of extracellular vesicles of mitochondrial origin altered in Down syndrome

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Science advances 2021-02-12 Down syndrome and Alzheimer's

    Mitochondrial dysfunction is an established hallmark of aging and neurodegenerative disorders such as Down syndrome (DS) and Alzheimer's disease (AD).

From across this topic

10 of the 1,352 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics